Skip to content


Odomzo (sonidegib) is a small molecule pharmaceutical. Sonidegib was first approved as Odomzo on 2015-07-24. It is used to treat skin neoplasms in the USA. It has been approved in Europe to treat basal cell carcinoma. The pharmaceutical is active against smoothened homolog. Odomzo's patents are valid until 2029-09-15 (FDA).
Trade Name Odomzo
Common Name Sonidegib
Indication basal cell carcinoma, skin neoplasms
Drug Class Hedgehog signaling inhibitors
Get full access now